SC
REGN icon

SouthState Corp’s Regeneron Pharmaceuticals REGN Stock Holding History

SouthState Corp’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1K Sell
21
-2
-9% -$1.36K ﹤0.01% 661
2026
Q1 		$17.8K Sell
23
-9
-28% -$6.89K ﹤0.01% 577
2025
Q4 		$24.7K Buy
32
+7
+28% +$4.75K ﹤0.01% 551
2025
Q3 		$14.1K Sell
25
-20
-44% -$11.3K ﹤0.01% 623
2025
Q2 		$23.6K Sell
45
-7
-13% -$3.91K ﹤0.01% 620
2025
Q1 		$33K Buy
52
+44
+550% +$30.3K ﹤0.01% 600
2024
Q4 		$5.7K Buy
8
+3
+60% +$2.52K ﹤0.01% 557
2024
Q3 		$5.26K Hold
5
– – ﹤0.01% 519
2024
Q2 		$5.25K Buy
5
+4
+400% +$3.88K ﹤0.01% 532
2024
Q1 		$962 Buy
+1
New +$951 ﹤0.01% 649
2023
Q2 		– Sell
-8
Closed -$6.57K – 637
2023
Q1 		$6.57K Sell
8
-25
-76% -$18.9K ﹤0.01% 551
2022
Q4 		$23.8K Hold
33
– – ﹤0.01% 450
2022
Q3 		$23K Buy
33
+8
+32% +$5.04K ﹤0.01% 451
2022
Q2 		$15K Hold
25
– – ﹤0.01% 533
2022
Q1 		$17K Hold
25
– – ﹤0.01% 549
2021
Q4 		$16K Hold
25
– – ﹤0.01% 513
2021
Q3 		$15K Buy
+25
New +$15.5K ﹤0.01% 458

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

SouthState Corp's REGN Position: Q2 2026 in Review

SouthState Corp reduced its Regeneron Pharmaceuticals (REGN) stake by 8.7% in Q2 2026, selling an estimated $1.36K and leaving 21 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #661.

SouthState Corp first reported a position in REGN in Q3 2021 and has held it in 17 quarters since. The position peaked at $33K in Q1 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • SouthState Corp held 21 shares of Regeneron Pharmaceuticals worth $13.1K as of Q2 2026.
  • SouthState Corp sold 2 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.36K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of SouthState Corp's portfolio in Q2 2026, its #661 holding.
  • SouthState Corp first reported a position in Regeneron Pharmaceuticals in Q3 2021 and has held it in 17 quarters since.
  • SouthState Corp's Regeneron Pharmaceuticals position peaked at $33K in Q1 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on SouthState Corp's 13F filing for Q2 2026, filed 6 Aug 2026.